Cognition-Enhancing Properties of Subchronic Phosphatidylserine (PS) Treatment in Middle-Aged Rats: Comparison of Bovine Cortex PS With Egg PS and Soybean PS

ARJAN BLOKLAND, PHD,* WIEL HONIG,† FRED BROUNS, PHD,‡ AND JELLE JOLLES, PHD†

From the *Faculty of Psychology and †Department of Psychiatry and Neuropsychology, Brain & Behavior Institute, and the ‡Novartis Nutrition Research Unit, Maastricht University, Maastricht, The Netherlands

ABSTRACT

There are various clinical and non-clinical studies that have indicated that phosphatidylserine (PS) treatment can improve cognitive functions in humans and other animals. However, treatment with PS derived from bovine cortex is not desirable because of possible transfer of infectious diseases. The present study investigated the cognition-enhancing properties of different types of PS in rats. Seventeen-month-old male Fischer 344 rats were treated daily with a dose of 15 mg/kg of PS derived from bovine cortex (BC-PS), soybean (S-PS), egg (E-PS), or vehicle (n = 9 for each group). The effects of treatment were evaluated in three different behavioral tests. An open field test was conducted to examine the effects of treatment on psychomotor behavior. Two other tests (Morris water escape task and two-way active avoidance) assessed treatment effects on the cognitive performance of the rats. Treatment with the different forms of PS did not affect the psychomotor or spatial discrimination performance of the rats. In accordance with previous studies, the cognition-enhancing effects of BC-PS were observed in the two-way active avoidance task. It appeared that the cognition-enhancing effects of S-PS were not different from those of BC-PS. The performance of rats treated with E-PS did not deviate from that of vehicle-treated rats. On the basis of the present study, it was concluded that S-PS, but not E-PS, may have comparable effects on cognition when compared with BC-PS.

INTRODUCTION

Phosphatidylserine (PS) is a naturally occurring phospholipid, and it plays an important role in the functioning of the membrane in neurons, e.g., maintenance of the cell’s internal environment, signal transduction, secretory vesicle release, cell-to-cell communication, and cell growth regulation. Thus, it may not be surprising that this phospholipid is considered to be an important brain cell nutrient. Aging is mostly associated with a deterioration in cognitive functions. This age-related impairment in cognitive functions is strongly related to a decrease in neurotransmitter and neuronal functions. Thus, treatment with PS, known to be structurally and functionally significant to brain cells, may attenuate the age-related loss of neuronal functions and thus improve cognitive functions.

It has been found that treatment with PS enhances cholinergic neurotransmission and also appears to increase the turnover of dopamine and norepinephrine in the brain. Another study has reported that brain sections preincubated with PS produce an increase in 3H]-a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid binding when compared with brain sections under control conditions. These data indicate that PS has an effect on neurotransmitters that may play a role in cognitive functions. Clinical studies have provided some evidence that PS can improve cognitive functions in demented patients, providing further evidence that the central effects of PS treatment have beneficial effects on cognitive functions. (for review, see Pepeu).

This research was financially supported by Novartis Nutrition. The research of Arjan Blokland has been made possible by a fellowship of the Royal Netherlands Academy of Arts and Sciences.

Key words: aging, cognition, rats, Morris task, phosphatidylserine (PS), learning
PS can be obtained from several sources. Bovine cortex PS (BC-PS) has been used to study the cognition-enhancing properties in rodents, but the use of BC-PS in humans is problematic because of possible transfer of infectious diseases (e.g., bovine spongiform encephalopathy). Another constraint against using BC-PS is that the yield of PS from bovine cortex is rather low. Alternative sources for PS are soybean (S-PS) and egg (E-PS). PS from these sources has a similar molecular makeup with respect to glycerol moiety and serine head group, but the fatty acid composition is different. S-PS is virtually devoid of arachidonic and docosahexaenoic acid, whereas BC-PS and E-PS are identically rich with these fatty acids.

The aim of the present study was to examine whether E-PS and S-PS had behavioral properties similar to those of BC-PS in the laboratory rat. Middle-aged rats, which usually show a modest natural decline in cognitive performance, were tested in three different tests. The first test was the open field test (OF), which is assumed to test the emotional state of rats but can also be regarded as a test for the psychomotor behavior of rats. The second test was the Morris water escape task (MWET), a test that assesses the spatial discrimination ability of rats. The last test was the two-way active avoidance test (TWAA), which was used to compare the results of the present experiment with those of previous studies with PS treatment.

MATERIALS AND METHODS

Animals

Thirty-six 12-mo-old Fischer 344 rats (F344/NHsd) were provided by Harlan Sprague-Dawley, Inc. (Houston, TX, USA). Five months after arrival in our laboratory, the rats were matched by body weight and placed into one of four different groups: vehicle, BC-PS, S-PS, and E-PS (n = 9 per group). At the start of the behavioral experiments, the rats were 17 months old.

Treatment

E-PS and S-PS were supplied by Lucas Meyer (Decatur, IL, USA); BC-PS was obtained from Avanti Polar Lipids (Alabaster, AL, USA). All solutions and the vehicle (0.75% Epikuron 110, a deoiled soybean lecithin, and 0.2% ethylene-diaminetetraacetic acid B; Lageron) were prepared by Lucas Meyer.

The rats were injected (intraperitoneally in a volume of 2 mL/kg) daily with one of the treatments. The dose of each PS treatment was 15 mg/kg, which was based on the behavioral active dose of BC-PS reported in previous studies. The rats were injected with the substance between 0800 and 0830 h and testing started at least 1 h after injection. Treatment started 4 days before the first (OF) test was conducted and was continued until behavioral testing was completed.

Behavioral Tests

Open field test. OF behavior was assessed in a square base (100 × 100 cm) divided into 36 equal squares by black lines. Two red fluorescent strip lights provided very dim illumination (approximately 3 lx) on the floor of the apparatus.

Immediately after a rat was placed in the center of the OF, its movements were scored. The total number of line crossings and the total time spent in the corner, wall, and center squares were recorded manually with an MS-DOS–compatible computer. Testing was done over 3 consecutive days in 5-min daily sessions.

Morris water escape task. Performance in the MWET was assessed in a water tank that consisted of a circular black tub, with a slightly sloping wall (polyethylene; inner dimensions: diameter at top = 153 cm, diameter at bottom = 143 cm, depth = 63 cm), filled with 43.5 cm of clear tap water at a temperature of approximately 22°C. The escape platform consisted of a black polyethylene cylinder (diameter = 10.8 cm) submerged 1.5 cm below the surface of the water. In this version, the water was not made opaque because a black escape platform is invisible in a black tank.

The water tank was situated in a room illuminated by white fluorescent strip lights. Abundant extra-maze cues were provided by the furniture in the room, including desks, computer equipment, a second water tank, the presence of the experimenter, and a radio on a shelf that was playing softly. All testing was done between 0900 and 1500 h.

A video camera, mounted in the center above the circular pool, provided a picture of the pool on a television monitor. The movements of a rat were automatically registered with a computer program (EthoVision, Noldus equipment, Wageningen, The Netherlands) and stored in an MS-DOS–compatible computer.

The animals received four trials during five acquisition sessions that were held on 5 consecutive days. A trial was started by placing a rat in the pool, facing the wall of the tank. Each of four starting positions (north, east, south, and west) was used once in a series of four trials; order was randomized. The escape platform was always in the same quadrant. A trial was terminated as soon as the rat had climbed onto the escape platform or when 60 s had elapsed, whichever event occurred first. After about 3 s, the rat was taken from the platform and put in a cage. After about 10 min, the next trial was started. Rats that did not find the platform within 60 s were put on the platform by the experimenter for about 3 s and then removed from the platform. After completion of the fourth trial (on the 5th d after completion of the probe trial; see below), the rat was returned to its home cage.

A probe trial was given after the fourth trial of the fifth daily session. In this additional trial, the platform was removed, and the time a rat spent in the four quadrants was measured for 30 s. In the probe trial, all rats started from the same position, opposite the quadrant where the escape platform had been positioned during acquisition.

Two-way active avoidance. Acquisition and retention of the TWAA task were assessed simultaneously in two shuttleboxes interfaced to an MS-DOS–compatible computer that controlled the trials and collected the data.

A rat was placed into the shuttlebox. The unconditioned stimulus (UCS; a 0.28-mA scrambled foot shock) started 10 s after the onset of the conditioned stimulus (CS; a tone and a light) if the rat had not made an avoidance response by moving to the other compartment during CS presentation. Both the UCS and the CS were terminated when the rat escaped to the other compartment or when 10 s had elapsed, whichever event occurred first. Retention/second acquisition was assessed 24 h after the first acquisition session.

The conditioning trials were separated by intertrial intervals of 20–60 s (average = 40 s). During this interval, the number of intertrial crossings was counted. The animals received 50 trials during both the acquisition and the retention/second acquisition sessions. The avoidance responses, i.e., moving to the other compartment of the test apparatus after presentation of the CS but before the shock was delivered, and the escape responses, i.e., moving to the other side during presentation of the foot shock, were recorded automatically. In addition, intertrial crossings, i.e., moving to the other side in the absence of UCS and CS, were registered.

Statistical Analysis

Open field test. The data of the OF test were aggregated over the 3 d to enhance reliability. Four aggregated variables are reported:

...
• mean time spent in the corner, wall, and center squares of the OF
• mean frequency of entering the compartments and crossing segments (i.e., of line crossings); this variable was used as a measure of horizontally directed motor activity
• mean frequency of rearing and leaning in the entire apparatus; this variable was used as a measure of vertically directed motor activity
• mean frequency of grooming bouts.

The mean time (in tenths of seconds) spent in the corner squares was transformed logarithmically (Ln[(t1 + t2 + t3)/3], where t1-3 refers to days 1–3 of testing) to remove inhomogeneity. A one-way analysis of variance (ANOVA) was used to test treatment effects on the different variables. The Student–Newman–Keuls post hoc test completed the statistical analysis (critical alpha value = 0.05). Two rats in the BC-PS treatment group did not show any activity during the 3 d. A Dixon extremity test indicated that these rats could be excluded from the statistical analysis.

Morris water escape task. For the analysis of the MWET data, the totals of four trials were calculated (performance per day). Three different parameters of spatial discrimination acquisition performance were analyzed: total distance swum to reach the platform, total latency to reach the platform, and average swimming speed.

To quantify the search behavior of rats during the probe trials, two different measures were analyzed: total time spent in the target quadrant and total time spent in the platform region.

The data of the acquisition were analyzed using a two-factorial design (treatment and blocks) with a repeated measures factor of blocks. A one-way ANOVA was used to test treatment effects in the probe trial. The Student–Newman–Keuls post hoc analysis evaluated the data in more detail (critical alpha value = 0.05).

Two-way active avoidance. The mean numbers of avoidances, escape responses, and intertrial crossings were calculated per block of 10 trials. Also, the number of barrier crossings during the adaptation phase was measured. It appeared that the data of the parameter avoidances were not normally distributed and, as a consequence, were transformed to rank scores (except for the analysis of the improvement of avoidance behavior, where the raw data were used). The data were analyzed with a two-factorial ANOVA (treatment and blocks) with blocks as a repeated measures factor. Post hoc analyses on the linear trend components evaluated the differences between treatment groups in more detail (Student–Newman–Keuls, critical α-value = 0.05).

RESULTS

Open Field Test

The time the rats spent in the different areas was not affected by treatment with the different types of PS (all associated probabilities of ANOVAs: P > 0.10; Fig. 1A). As shown in Figure 1B, treatment with different sources of PS did not affect the activity of the rats in the OF test (all associated probabilities of ANOVAs: P > 0.10). The results of rearing and grooming behavior are not shown because no treatment effects were found (all associated probabilities of ANOVAs: P > 0.10).

Morris Water Escape Task

Figure 2 shows the data of the different parameters of MWET behavior. All rats readily learned the task (distance: block effect
The rats learned to avoid the foot shock during the session with 50 trials (blocks: $F[4,128] = 14.33, P < 0.01$, Fig. 3A). In the TWAA test, a treatment effect was found for the number of avoids by the rats made during the session of 50 trials ($F[3,32] = 3.43, P < 0.05$). Post hoc analysis showed that the rats treated with BC-PS and S-PS made more avoids during the session of 50 trials than did the vehicle-treated rats. The performance of rats treated with E-PS did not differ from that of rats in the other groups. During the second acquisition session, another performance improvement was observed (blocks: $F[4,128] = 21.13, P < 0.01$). There was a tendency of treatment effect for the number of avoids made by the rats ($F[3,32] = 2.83, P < 0.06$, Fig. 3A). Post hoc analysis on the general mean indicated that the BC-PS–treated rats made more avoids than did the vehicle-treated rats. The performance of rats treated with S-PS or E-PS did not differ from that of rats in the other treatment groups.

There was also an indication that treatment with PS affected the number of escapes during the first acquisition session ($F[3,32] = 21.13, P < 0.01$). Post hoc analysis showed that the rats treated with BC-PS and S-PS made more escapes during the session of 50 trials than did the vehicle-treated rats. The performance of rats treated with E-PS did not differ from that of rats in the other groups. There was also an indication that treatment with PS affected the number of escapes during the first acquisition session (treat-
ment × blocks: $F[12,128] = 2.46, P < 0.01$, Fig. 3A). This interaction effect was difficult to interpret but was most likely related to the fluctuations in the behavior of the vehicle-treated rats. Although the BC-PS group seemed to show more escape responses than the vehicle-treated group during the second acquisition (Fig. 3B), this was not confirmed statistically (treatment: $F[3,32] = 0.16$, NS). However, a treatment × blocks effect was found ($F[12,128] = 1.89, P < 0.05$), suggesting that the decrease in escape responses was different for the treatment groups. There were no treatment effects on the measure intertrial crossings (all associated probabilities of ANOVAs: $P > 0.10$).

**Body Weight**

During the course of treatment, the body weights of the rats decreased (weeks: $F[4,128] = 352.93, P < 0.01$) and diverged for the groups treated with different types of PS (weeks × treatment: $F[12,128] = 5.33, P < 0.01$, Fig. 4). This difference was due to the lower body weights of the E-PS–treated rats during the course of testing. During week 5, the rats treated with E-PS weighed less than the rats in the other treatment groups ($F[3,32] = 6.54, P < 0.01$).

**DISCUSSION**

The present study has examined the effects of treatment with different types of PS on behavior in middle-aged rats. Based on previous reports on the effects of BC-PS in rats in avoidance tasks, all substances were given in a dose of 15 mg/kg intraperitoneally. Based on the comparable molecular makeup of the substances, it was assumed that E-PS and S-PS would have a bioavailability similar to that of BC-PS.

In the OF and MWET tests, no effects of PS treatment were observed. The lack of effect of PS on behavioral activity in the OF test corroborates findings from a previous study. The OF test has been found to be a very sensitive test for pharmacologic treatments. However, no change in behavior in the OF test can also imply that the treatments had no negative side effects. Because no effects were found in this test, it was concluded that PS treatment did not affect behavioral activity or emotional reactivity in rats. In addition, it could be concluded that PS treatment does not have adverse effects on the physiologic state of the rats.

There are only a few substances that have been shown to improve the performance of old rats in the MWET. The MWET is assumed to be a task with a high face validity for testing cognition-enhancing compounds. It can be argued that the limited number of substances that can improve MWET performance reflects the present status of cognition enhancers. At present, tacrine (Cognex, Boston, MA, USA) is the only approved medication for the treatment of the cognitive dysfunctions in Alzheimer’s disease. However, it has been shown that tacrine has no beneficial effects in the MWET task in middle-aged rats, but it has been shown to be effective in other animal models of dementia. However, no direct comparison can be made between the effects of tacrine and PS until these drugs are tested in the same study.
The improved performance of rats treated with BC-PS in the TWAA test corroborates previous findings in a similar task. Therefore, avoidance tasks (i.e., active avoidance and passive avoidance) can be considered a sensitive test for PS treatment. S-PS treatment had similar effects when compared with BC-PS treatment, i.e., the performance of this group was better than that of the vehicle-treated group. A previous study also found ameliorating effects of BC-PS and S-PS in a scopolamine-induced memory deficit as assessed by an avoidance task. The performance of the group treated with E-PS did not differ from that of the vehicle group on any measure. Although there was no statistically reliable difference between the E-PS and S-PS groups, the mean performance of the rats treated with S-PS was higher than that of the E-PS–treated rats.

The reason E-PS produced inactivity whereas S-PS produced activity in the TWAA test is not clear. Because the fatty acid composition of E-PS (which is relatively high in arachidonic acid and docosahexaenoic acid) versus that of S-PS more closely matches the composition of brain phospholipids, which is high in linoleic acid, we were surprised by this observation. Thus, we can only speculate that the E-PS may have lost bioactivity because of a breakdown of the bioactive compound during processing or storage.

Other studies with PS treatment have used higher doses of BC-PS and S-PS. For example, in a recent study by Sakai et al., S-PS or BC-PS was given in a dose of 60 mg/kg (intraperitoneally). However, in that study, the acute effects of a single PS injection were investigated. In another study, PS was given for 12 weeks in a dose of 50 mg/kg/d to aged, impaired rats. In both studies, PS treatment improved the performance of the rats. Drago et al. tested the effects of PS in a dose range of 5–20 mg/kg intraperitoneally, and they found cognition-enhancing effects of PS. Also, other studies have indicated that a dose of 15 mg/kg exerts effects on the brain. These data imply that high doses of PS can be applied to obtain a beneficial effect. Apparently, there is a wide therapeutic window for PS treatment.

A final point for discussion is related to the effects of PS treatment on body weight. The decline in body weight in rats subjected to behavioral tests is normal. The physical effort of the rats made in the different tests and the mild stress the rats experienced are assumed to lead to a decrease in the freely feeding body weight. PS has been reported to act protectively against stress-induced behavioral and autonomic changes. However, this cannot explain the lack of difference between the vehicle and BC-PS groups and does not account for the observation that E-PS–treated rats reduced their weight more rapidly than did the rats in the other treatment (including vehicle) groups.

In summary, the present study has shown that BC-PS improved the performance of middle-aged rats in a TWAA task. S-PS, but not E-PS, appeared to have effects similar to those of BC-PS. However, another cognitive task did not show any beneficial effect of PS treatment. PS treatment did not affect the psychomotor performance of rats as assessed in an OF test. On the basis of the present data, it was concluded that S-PS may be regarded as a possible alternative to BC-PS for treating cognitive dysfunctions.

SUMMARY

The cognition-enhancing properties of subchronic treatment with different types of PS were investigated in middle-aged rats. It was found that treatment with S-PS, but not E-PS, had positive effects similar to those of BC-PS in an avoidance task.

REFERENCES

6. The reason E-PS produced inactivity whereas S-PS produced activity in the TWAA test is not clear. Because the fatty acid composition of E-PS (which is relatively high in arachidonic acid and docosahexaenoic acid) versus that of S-PS more closely matches the composition of brain phospholipids, which is high in linoleic acid, we were surprised by this observation. Thus, we can only speculate that the E-PS may have lost bioactivity because of a breakdown of the bioactive compound during processing or storage.

(For an additional perspective, see Editorial Comments/Opinions)